Patients with lung cancer are usually accompanied by mutations of epidermal growth factor receptor (EGFR), tumor protein p53 (P53), and KRAS proto-oncogene (KRAS) (Bennett et al., 1999; Roman et al., 2018; Wu and Shih, 2018; Adderley et al., 2019). Here, EGFR is linked to lung cancer.